Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
It is widely recognized that activated hepatic stellate cells (HSC) play a pivotal role in development of liver fibrosis. A platelet-derived growth factor (PDGF) is the most potent mitogen for HSC. The aim of this study was to examine the effect of imatinib mesylate (STI-571, Gleevec), a clinically used PDGF receptor (PDGFR) tyrosine kinase inhibitor, on development of experimental liver fibrosis. The rat model of pig serum-induced hepatic fibrosis was used to assess the effect of daily oral administration of STI-571 on the indexes of fibrosis. STI-571 markedly attenuated development of liver fibrosis and hepatic hydroxyproline and serum fibrosis markers. The number of α-smooth muscle actin-positive cells and mRNA expression of α 2-(I)-procollagen, tissue inhibitor of metalloproteinases-1, and transforming growth factor-β were also significantly suppressed by STI-571. Our in vitro study showed that STI-571 markedly attenuated PDGF-BB-induced proliferation and migration and α-SMA and α 2-(I)-procollagen mRNA of activated HSC in a dose-dependent manner. STI-571 also significantly attenuated PDGF-BB-induced phosphorylation of PDGFR-β, MEK1/2, and Akt in activated HSC. Because STI-571 is widely used in clinical practice, it may provide an effective new strategy for antifibrosis therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Wong, L., Yamasaki, G., Johnson, R. J., & Friedman, S. L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117497 · Cited by 304 · cited 3×
“It has been reported that PDGFR- is mainly upregulated after CCl4-induced liver injury (26, 32).”
BackgroundTissue inhibitors of metalloproteinases in liver fibrosis
Iredale, J. P. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(96)00118-5 · Cited by 165
Cited by
Macrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Hemmann, S., Graf, J., Roderfeld, M., & Roeb, E. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.003 · Cited by 509
Hepatic Stellate Cells and Liver Fibrosis
Moreira, R. K. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-1728-hscalf · Cited by 452
Metadata
- Authors
- Yoshiji, H., Noguchi, R., Kuriyama, S., Ikenaka, Y., Yoshii, J., Yanase, K., Namisaki, T., Kitade, M., Masaki, T., & Fukui, H.
- Venue
- American Journal of Physiology-Gastrointestinal and Liver Physiology
- Publisher
- American Physiological Society
- Published
- 2005-05
- Volume
- 288
- Issue
- 5
- Pages
- G907-G913
- ISSN
- 0193-1857 (ISSN-L)
- 1522-1547
- OpenAlex
- W2108518428
- Cited by
- 145
- References
- 3
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.